Radical prostatectomy: Influence on serum and urinary androgen levels

Prostate

Volumn 70, Issue 2, 2010, Pages 200-205

  Olsson, Mats ^a   Ekström, Lena ^a   Schulze, Jenny ^a   Kjellman, Anders ^a   Akre, Olof ^a   Rane, Anders ^a   Gustafsson, Ove ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dihydrotestosterone; Gonadotropins; Inhibin B; Prostate cancer; Radical prostatectomy

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTERONE; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

AGED; ANDROGENS; ANDROSTANE-3,17-DIOL; ANDROSTERONE; CROSS-SECTIONAL STUDIES; DIHYDROTESTOSTERONE; FOLLICLE STIMULATING HORMONE; GLUCURONIDES; HUMANS; INHIBINS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 73449094875     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21053     Document Type: Article

References (24)

1. Wilson JD. Role of dihydrotestosterone in androgen action. Prostate Suppl 1996;6:88-92.
2. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92(2):903-910.
3. Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003;14(10): 473-479.
4. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J urol 2004;172(4 Pt 1):1297-1301.
5. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelson A, Bratt O, Damber JE, Hellstrom K, Hellstrom M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Tornblom M, Widmark A, Stattin P. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41(6):456-477.
6. Khera M. Androgens and erectile function: A case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009;6: (Suppl 3):234-238.
7. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009;6(4):1165-1170.
8. Bantis A, Zissimopoulos A, Athanasiadou P, Gonidi M, Agelonidou E, Strataki A, Matthaios D, Tsartsarakis A. Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements. Hell J Nucl Med 2007;10(1):56-61.
9. Madersbacher S, Schatzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P, Zidek T, Marberger M. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 2002;60(5):869-874.
10. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160(2):449-453.
11. Phadke MA, Vanage GR, Sheth AR. Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. Prostate 1987;10(2):115-122.
12. Pardridge WM. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 1986;15(2):259-278.
13. Chung BC, Choo HY, Kim TW, Eom KD, Kwon OS, Suh J, Yang J, Park J. Analysis of anabolic steroids using GC/MS with selected ion monitoring. J Anal Toxicol 1990;14(2):91-95.
14. Garle M, Ocka R, Palonek E, Bjorkhem I. Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program. Evaluation of 28 cases. J Chromatogr B Biomed Appl 1996;687(1):55-59.
15. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47(1):52-58.
16. Coutts SB, Kicman AT, Hurst DT, Cowan DA. Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: Changes in urinary hormone profile. Clin Chem 1997;43(11): 2091-2098.
17. Kuhn JM, Rieu M, Laudat MH, Forest MG, Pugeat M, Bricaire H, Luton JP. Effects of 10 days administration of percutaneous dihydrotestosterone on the pituitary-testicular axis in normal men. J Clin Endocrinol Metab 1984;58(2):231-235.
18. Cailleux-Bounacer A, Rohmer V, Lahlou N, Lefebvre H, Roger M, Kuhn JM. Impact level of dihydrotestosterone on the hypothalamic-pituitary-leydig cell axis in men. Int J Androl 2009;32(1):57-65.
19. Canovatchel WJ, Volquez D, Huang S, Wood E, Lesser ML, Gautier T, Imperato-McGinley J. Luteinizing hormone pulsatility in subjects with 5-alpha-reductase deficiency and decreased dihydrotestosterone production. J Clin Endocrinol Metab 1994; 78(4):916-921.
20. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002;99(21):13589-13594.
21. Handa RJ, Pak TR, Kudwa AE, Lund TD, Hinds L. An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5alpha-androstane-3beta, 17beta-diol. Horm Behav 2008;53(5): 741-752.
22. Lackner JE, Maerk I, Koller A, Bieglmayer C, Marberger M, Kratzik C, Schatzl G. Serum inhibin - Not a cause of low testosterone levels in hypogonadal prostate cancer? Urology 2008;72(5):1121-1124.
23. Pierrepoint CG, Davies P, Millington D, John B. Evidence that the deferential vein acts as a local transport system for androgen in the rat and the dog. J Reprod Fertil 1975;43(2):293-303.
24. Boulanger P, Desaulniers M, Bleau G, Roberts KD, Chapdelaine A. Sex steroid concentrations in plasma from the canine deferential vein. J Endocrinol 1983;96(2):223-228.